Qube Research & Technologies (QRT)’s Janux Therapeutics JANX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.8M	Buy	702,057 +504,912	+256%	+$7.31M	0.01%	1247
2026 Q1	$2.74M	Sell	197,145 -18,860	-9%	-$259K	﹤0.01%	1986
2025 Q4	$2.98M	Buy	216,005 +105,156	+95%	+$2.47M	﹤0.01%	2057
2025 Q3	$2.71M	Sell	110,849 -137,024	-55%	-$3.34M	﹤0.01%	2087
2025 Q2	$5.73M	Sell	247,873 -55,321	-18%	-$1.46M	0.01%	1619
2025 Q1	$8.19M	Buy	303,194 +73,804	+32%	+$2.78M	0.01%	1256
2024 Q4	$12.3M	Buy	+229,390	New	+$12.1M	0.02%	973
2024 Q3	–	Sell	-10,034	Closed	-$420K	–	3722
2024 Q2	$420K	Buy	+10,034	New	+$471K	﹤0.01%	2201
2023 Q4	–	Sell	-8,735	Closed	-$88K	–	4540
2023 Q3	$88K	Sell	8,735 -3,906	-31%	-$45K	﹤0.01%	2694
2023 Q2	$150K	Buy	+12,641	New	+$169K	﹤0.01%	1864
2021 Q3	–	Sell	-14,309	Closed	-$357K	–	2498
2021 Q2	$357K	Buy	+14,309	New	+$319K	﹤0.01%	1470

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Qube Research & Technologies (QRT)'s JANX Position: Q2 2026 in Review

Qube Research & Technologies (QRT) increased its Janux Therapeutics (JANX) stake by 256% in Q2 2026, buying an estimated $7.31M and bringing the position to 702,057 shares worth $10.8M. The position accounts for 0.01% of the portfolio, ranked #1247.

Qube Research & Technologies (QRT) first reported a position in JANX in Q2 2021 and has held it in 11 quarters since. The position peaked at $12.3M in Q4 2024. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Qube Research & Technologies (QRT) held 702,057 shares of Janux Therapeutics worth $10.8M as of Q2 2026.
Qube Research & Technologies (QRT) bought 504,912 Janux Therapeutics shares in Q2 2026, an estimated $7.31M.
Janux Therapeutics made up 0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #1247 holding.
Qube Research & Technologies (QRT) first reported a position in Janux Therapeutics in Q2 2021 and has held it in 11 quarters since.
Qube Research & Technologies (QRT)'s Janux Therapeutics position peaked at $12.3M in Q4 2024.
197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.